chr16-574114-A-G
Variant summary
Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1
The NM_004204.5(PIGQ):c.40A>G(p.Thr14Ala) variant causes a missense change. The variant allele was found at a frequency of 0.448 in 1,609,226 control chromosomes in the GnomAD database, including 166,056 homozygotes. In-silico tool predicts a benign outcome for this variant. 13/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★). Another nucleotide change resulting in the same amino acid substitution has been previously reported as Likely benign in UniProt.
Frequency
Consequence
NM_004204.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -20 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.461 AC: 70000AN: 152004Hom.: 16538 Cov.: 34
GnomAD3 exomes AF: 0.487 AC: 119419AN: 245364Hom.: 30271 AF XY: 0.486 AC XY: 64883AN XY: 133370
GnomAD4 exome AF: 0.447 AC: 650813AN: 1457106Hom.: 149486 Cov.: 45 AF XY: 0.451 AC XY: 326652AN XY: 724892
GnomAD4 genome AF: 0.461 AC: 70082AN: 152120Hom.: 16570 Cov.: 34 AF XY: 0.469 AC XY: 34891AN XY: 74384
ClinVar
Submissions by phenotype
not provided Benign:2
Benign, criteria provided, single submitter | clinical testing | GeneDx | Feb 08, 2019 | - - |
Benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
not specified Benign:1
Benign, criteria provided, single submitter | clinical testing | Unidad de Genómica Garrahan, Hospital de Pediatría Garrahan | Jul 15, 2024 | This variant is classified as Benign based on local population frequency. This variant was detected in 71% of patients studied in a panel designed for Epileptic and Developmental Encephalopathy and Progressive Myoclonus Epilepsy. Number of patients: 66. Only high quality variants are reported. - |
Epilepsy Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 04, 2025 | - - |
Developmental and epileptic encephalopathy, 77 Benign:1
Benign, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Jul 14, 2021 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at